ProtoKinetix

ProtoKinetix EBITDA Growth YoY

The Year-over-Year EBITDA Growth of ProtoKinetix (PKTX) as of Nov 19, 2026 is -52.52 %. In the previous year, Year-over-Year EBITDA Growth was 19.01 % — a change of -376.20% (lower).

EBITDA Growth YoY

-52.52 %

YoY

-376.20%

Last updated:

Year-over-Year EBITDA Growth of ProtoKinetix is 2025 -52.52 % . Year-over-Year EBITDA Growth of ProtoKinetix was 2024 19.01 % . It decreases by -376.20% lower compared to the previous year.

The ProtoKinetix EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2018
19.61 USD
Jan 1, 2019
-245.82 USD
Jan 1, 2020
-82.15 USD
Jan 1, 2021
69.56 USD
Jan 1, 2022
23.02 USD
Jan 1, 2023
82.20 USD
Jan 1, 2024
19.01 USD
Jan 1, 2025
-52.52 USD
The ProtoKinetix EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
-52.52 %-376.20%
19.01 %-76.87%
82.20 %+257.05%
23.02 %-66.90%
69.56 %-184.67%
-82.15 %-66.58%
-245.82 %-1,353.41%
19.61 %+2,259.24%
0.83 %-103.94%
-21.09 %-90.72%
-227.24 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ProtoKinetix Stock analysis

What does ProtoKinetix do? ProtoKinetix Inc. is a Canadian biotechnology company focused on the development of glycoproteins for therapeutic applications. The company was founded in 2005 and is headquartered in Marietta, USA. ProtoKinetix specializes in the research and development of AAGP® (Anti-Aging Glycopeptide) as biopharmaceuticals. These proprietary glycoproteins have the ability to protect cells and can be used in various therapeutic applications for improving damage in physical injury, spinal cord injury, diabetes, transplantation, and retinal diseases. In addition to the medical field, ProtoKinetix is also developing its patented technology for use in bio-agriculture and animal healthcare. It has a subsidiary that holds the rights to use and distribute AAGP® and its patents. ProtoKinetix's business model involves licensing its glycoprotein technology for various applications, including biopharmaceuticals, bioprocessing industries, and cell protection management for regenerative medicine and stem cell preparations. The company has established partnerships with other biotech companies to integrate its AAGP® technology into their product pipelines. ProtoKinetix's flagship product is the AAGP® protein solution, which is used as a medication in regenerative medicine, organ transplantation, eye healing, and animal health. It is also interested in researching the application of AAGP® in crop farming to increase yields and improve soil quality. ProtoKinetix is poised to play a significant role in the development of glycoproteins as future medicines and therapeutic technologies in various industries. It not only has the potential to explore healing medical products but also aims to enhance agriculture and animal care. ProtoKinetix represents an excellent example of a biotechnology company focused on improving the healthcare and agricultural industries. ProtoKinetix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ProtoKinetix stock

Year-over-Year EBITDA Growth of ProtoKinetix is -52.52 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth ProtoKinetix since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's ProtoKinetix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — ProtoKinetix

All Key Metrics — ProtoKinetix